Surgical interventions in inflammatory bowel disease: Indications, techniques, outcomes, and future directions

Table 1 Indications for surgery in ulcerative colitis and Crohn’s disease

Feature	Ulcerative colitis	Crohn’s disease
Main elective indication	Medically refractory pancolitis/proctitis despite optimized biologics	Fibro-stenotic obstruction, penetrating complications, failure of medical therapy
Cancer/dysplasia indication	Visible or high-grade dysplasia, multifocal or nonresectable lesions	Colitis-associated dysplasia in colonic CD; often managed similarly to UC
Emergency indications	Toxic megacolon, perforation, massive hemorrhage, fulminant colitis	Perforation, uncontrolled hemorrhage, fulminant colitis, sepsis from penetrating disease
Typical index operation	Subtotal colectomy with end ileostomy or proctocolectomy with IPAA	Ileocolic resection, segmental resection, or stricturo-plasty

UC: Ulcerative colitis; CD: Crohn’s disease; IPAA: Ileal pouch-anal anastomosis.

Table 2 Key surgical options in ulcerative colitis

Procedure	Main indication	Advantages	Limitations/risks
Subtotal colectomy with end ileostomy	Emergency toxic megacolon, perforation, severe colitis	Rapid source control; avoids pelvic dissection	Permanent stoma if no later reconstruction; rectal stump issues
Total proctocolectomy + IPAA (J-pouch)	Medically refractory UC; dysplasia/cancer	No colon/rectum; continence preserved; no permanent stoma	Pouchitis, pelvic sepsis, sexual/urinary dysfunction, pouch failure
Total colectomy + ileorectal anastomosis	Mild rectal disease; fertility concerns; high-risk for IPAA	Easier operation, better pelvic nerve preservation	Ongoing rectal disease; cancer surveillance required
Permanent end ileostomy	Unfit for restorative surgery; failed pouch; patient choice	Technically straightforward; reliable symptom control	Body image concerns; stoma complications; appliance dependence

IPAA: Ileal pouch-anal anastomosis; UC: Ulcerative colitis.

Table 3 Ileal pouch-anal anastomosis vs permanent end ileostomy in ulcerative colitis

Domain	IPAA (ileal pouch-anal anastomosis)	Permanent end ileostomy
Disease control	Removes colon/rectum; pouchitis common long-term	Removes colon/rectum; no pouchitis risk
Bowel function	5-8 BMs/day, some urgency/soilage; improves over time	4-6 stoma emptyings/day; predictable but appliance-dependent
Major complications	Pouchitis, pelvic sepsis, strictures, pouch failure	Parastomal hernia, skin problems, retraction/prolapse
Quality of life (global)	Generally “better or much better” than pre-op in > 80% of patients	Often improved vs pre-op; many report good HRQOL but with body-image issues
Sexual function	Small but real risk of pelvic nerve injury; most maintain function	Less pelvic dissection if rectum spared; function often preserved
Decisional aspects	More complex risk–benefit discussion; strong preference to avoid stoma	Some patients prefer predictable stoma to fear of pouch failure

IPAA: Ileal pouch-anal anastomosis; HRQOL: Health-related quality of life.

Table 4 Two-stage vs three-stage ileal pouch-anal anastomosis

Feature	Two-stage IPAA	Three-stage IPAA
Typical sequence	Proctocolectomy + IPAA + diverting ileostomy → ileostomy closure	Subtotal colectomy + end ileostomy → completion proctectomy + IPAA + DI → closure
Usual candidates	Medically optimized, lower-risk, stable patients	Acute severe colitis, high-dose steroids, biologic rescue, malnutrition
Short-term morbidity	Comparable to 3-stage in modern series	Comparable; offers safer route in very sick patients
Pouch failure/leak	No significant difference vs 3-stage	No significant difference vs 2-stage
Quality of life after closure	Similar global and functional PROs between strategies	Similar global and functional PROs

PRO: Patient-reported outcomes; IPAA: Ileal pouch-anal anastomosis; DI: Diverting ileostomy.

Table 5 Common operations in Crohn’s disease

Operation/technique	Typical indication	Bowel preservation	Key concerns/outcomes
Ileocolic resection	Terminal ileal CD with obstruction or penetrating disease	Limited	High endoscopic recurrence; anastomotic strategy important
Heineke-Mikulicz strictureplasty	Short (< 10 cm) fibrostenotic small-bowel strictures	High	Good long-term patency; avoid in severe inflammation or dysplasia
Finney/michelassi strictureplasty	Long or multiple strictures, risk of short bowel	Very high	Technically demanding; bacterial overgrowth risk in long segments
Kono-S anastomosis	Ileocolic resection where recurrence risk is high	N/A	Similar morbidity; may reduce anastomotic complications and reintervention
Perianal seton drainage	Complex perianal fistulas with abscess/sepsis	N/A	Essential bridge to medical therapy; often long-term seton use

N/A: Not applicable; CD: Crohn’s disease.

Table 6 Laparoscopic vs robotic vs open inflammatory bowel disease surgery

Aspect	Open surgery	Laparoscopic surgery	Robotic surgery
Incision/access	Midline laparotomy	Multiple small ports	Multiple robotic ports; articulated instruments
Postoperative pain	Highest	Reduced vs open	Similar or slightly less vs laparoscopy in some series
Length of stay	Longest	Shorter vs open	Comparable to laparoscopy; sometimes shorter in complex pelvic cases
Conversion to open	N/A	Low but present	Very low in expert centers; longer operative time
Cost/resources	Lowest direct device cost	Moderate	Highest device and OR cost

N/A: Not applicable; OR: Odds ratio.

Table 7 Early surgery vs prolonged medical therapy in localized ileocaecal Crohn’s disease

Aspect	Early ileocolic resection	Prolonged/optimized medical therapy (e.g., anti-TNF)
Primary aim	Rapid symptom control and removal of diseased segment	Long-term inflammation control and bowel preservation
Short-term outcomes	Faster symptom relief; fewer steroids; good QoL	Avoids surgical risk initially; some avoid surgery long-term
Long-term surgery need	Many will need further surgery over time	Substantial proportion ultimately require surgery
Strategy implications	Favored for stricturing/penetrating localized disease in fit patients	Favored when extensive small bowel involvement or high surgical risk

TNF: Tumor necrosis factor; QoL: Quality of life.

Table 8 Risk factors for postoperative recurrence in Crohn’s disease

Risk factor	Effect on recurrence
Active cigarette smoking	Strongest modifiable predictor; higher endoscopic and surgical recurrence
Penetrating phenotype, perianal CD	Increased early endoscopic and clinical recurrence
Prior intestinal resection	Higher risk of further surgery and earlier recurrence
Extensive small-bowel resection	Increased recurrence and nutritional complications
Absence or delay of biologic prophylaxis	Higher endoscopic recurrence vs early anti-TNF therapy

CD: Crohn’s disease; TNF: Tumor necrosis factor.